GFAP antibody (Cytosolic, Intracellular)
Quick Overview for GFAP antibody (Cytosolic, Intracellular) (ABIN7886319)
Target
See all GFAP AntibodiesReactivity
Host
Clonality
Conjugate
Application
-
-
Binding Specificity
- AA 27-39, Cytosolic, Intracellular
-
Purpose
- A Guinea Pig Polyclonal Antibody to GFAP
-
Cross-Reactivity
- Mouse, Rat
-
Cross-Reactivity (Details)
- The antibody will not recognize GFAP from human samples.
-
Predicted Reactivity
- Mouse - 10,13 amino acid residues identical The antibody will not recognize GFAP from human samples
-
Characteristics
- Intracellular
-
Purification
- Affinity purified on immobilized antigen.
-
Immunogen
- (C)RHLGTIPRLSLSR, corresponding to amino acid residues 27-39 of rat Glial fibrillary acidic protein
-
Isotype
- IgG
-
-
-
-
Application Notes
-
WB: 1:500
FC: The optimal concentration should be determined by the user
ICC: The optimal concentration should be determined by the user
IHC: 1:600-1:1200
IP: The optimal concentration should be determined by the user
-
Comment
-
Negative Control: (ABIN7235599)
Blocking Peptide: (ABIN7235599)
-
Restrictions
- For Research Use only
-
-
-
Format
- Lyophilized
-
Reconstitution
- 25 μL, 50 μL or 0.2 mL double distilled water (DDW), depending on the sample size.
-
Concentration
- 0.8 mg/mL
-
Buffer
- PBS pH 7.4, 1 % BSA with 0.05 % sodium azide
-
Preservative
- Sodium azide
-
Precaution of Use
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Storage
- -20 °C
-
Storage Comment
- The antibody ships as a lyophilized powder at room temperature. Upon arrival, it should be stored at -20°C
-
-
- GFAP (Glial Fibrillary Acidic Protein (GFAP))
-
Alternative Name
- GFAP
-
Background
-
Synonyms: Glial fibrillary acidic protein
Description: Glial fibrillary acidic protein (GFAP) is a key intermediate filament (IF) III protein responsible for maintaining the mechanical strength of glia cells by supporting their cytoskeleton structure. GFAP is expressed in astrocytes in the CNS, non-myelinating Schwann cells in the PNS, and enteric glial cells1.GFAP has a structural organization that is typical to class III IF proteins: it has a head, rod, and tail domains. The N-terminal head domain is important for filament formation and the C-terminal domain is important for oligomerization2.GFAP is encoded by a single gene mapped to human chromosome 17q21. To date, 10 isoforms/splice variants have been identified. GFAP is tightly regulated: both at mRNA transcription level and by phosphorylation and other post-translational modifications. A number of growth factors such as CNTF, FGF and TGF-β can induce GFAP gene transcription activation leading to increased GFAP protein levels3.Single nucleotide polymorphism (SNP) in GFAP results in the formation of Rosenthal fibers that cause Alexander Disease, hence, GFAP is a potential drug target for the treatment of this disease. A number of GFAP mutations were found in the coding and in the promoter regions of Alexander disease patients4.GFAP gene activation and protein induction appear to play a critical role in astroglia cell activation (astrogliosis) following CNS injuries and neurodegeneration. GFAP protein and its breakdown products are rapidly released into biofluids following traumatic brain and spinal cord injuries and stroke, making them strong candidate biomarkers for such neurological disorders5.
-
Gene ID
- 24387
-
NCBI Accession
- NM_002055
-
UniProt
- P47819
Target
-